Je,
I need to take my own advise to you
Patience+ to suffer with from the latin
share overhang is cement, 50lb weight in your hands and your treading water it will work its way out with approval, no more
dilution etc.
no main stream print, cnbc, bloomberg, invest.bus.daily once we
make the print:
R+D valuation for our pps, speculation, big banks, etc. buy,buy,buy, buy out talk, spread sheets , big pharma kicks the
tires seriously and sizes up our team and ceo
in lay persons terms this share struct. back of matchbook
figures,
cut every thing in half , so with todays share structure
90 cents from first run is equal to 45 cents today
so currently we are 16 cents on first run
We will need print to get that higher pe ratio and it will come
snup says suddenly on no look back move, plan accordingly
powers that be seem to be deliberately planning it that way!
realize also if they go mums the word until approval we will be
unable to hit the ground running regarding revenues. this is
worst case scenario and delay talk will be endless on this board
earnings call in mid june shoud Move our stock finally up I know
Iknow we generally go down every cc but this one will be different
I think we will get meat on the bone, and main stream print by this conference call, very reasonable to assume this.
now, can we go mums the word until mid june? possibly
could we have no generic launches because of focus on sequest oxy?
good possibility,
at the minimum seeking alpha is remiss on giving an update
on eli 200 phase 3 pass, fda date July 14 so looking
for that in April
valeant pharma? oops, everyone enjoy your afternoon!
snup
Market Data 
Markets 
AI
